You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFluvoxamine
Accession NumberDB00176  (APRD00425)
TypeSmall Molecule
GroupsApproved, Investigational
Description

Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder.
Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database comprised of approximately 35,000 patients. It was launched in the US in December 1994 and in Japan in June 1999. As of the end of 1995, more than 10 million patients worldwide have been treated with fluvoxamine.

Structure
Thumb
Synonyms
Fluvoxamina
Fluvoxamine
Fluvoxaminum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act Fluvoxaminetablet50 mgoralActavis Pharma Company2004-08-13Not applicableCanada
Act Fluvoxaminetablet100 mgoralActavis Pharma Company2004-08-13Not applicableCanada
Ava-fluvoxaminetablet100 mgoralAvanstra Inc2011-08-222014-08-21Canada
Ava-fluvoxaminetablet50 mgoralAvanstra Inc2011-08-222014-08-21Canada
Bci Fluvoxamine Tabletstablet100.0 mgoralBaker Cummins Inc2005-07-042006-10-03Canada
Bci Fluvoxamine Tabletstablet50.0 mgoralBaker Cummins Inc2005-07-042006-10-03Canada
Dom-fluvoxaminetablet100 mgoralDominion Pharmacal2000-02-23Not applicableCanada
Dom-fluvoxaminetablet50 mgoralDominion Pharmacal2000-02-23Not applicableCanada
Fluvoxamine Maleatetablet25 mg/1oralStat Rx USA2008-04-14Not applicableUs
Fluvoxamine Maleatetablet, coated100 mg/1oralANI Pharmaceuticals, Inc.2011-08-09Not applicableUs
Fluvoxamine Maleatetablet, coated50 mg/1oralANI Pharmaceuticals, Inc.2011-08-09Not applicableUs
Fluvoxamine Maleatetablet, coated25 mg/1oralANI Pharmaceuticals, Inc.2011-08-09Not applicableUs
Fluvoxamine Maleatetablet50 mg/1oralREMEDYREPACK INC.2012-10-15Not applicableUs
Fluvoxamine Maleatetablet100 mg/1oralREMEDYREPACK INC.2013-09-11Not applicableUs
Fluvoxamine Maleatetablet, coated50 mg/1oralAidarex Pharmaceuticals LLC2011-08-09Not applicableUs
Fluvoxamine Tabletstablet100 mgoralIvax Pharmaceuticals IncorporatedNot applicableNot applicableCanada
Fluvoxamine Tabletstablet50 mgoralIvax Pharmaceuticals IncorporatedNot applicableNot applicableCanada
Fluvoxamine-100tablet100 mgoralPro Doc Limitee1998-04-10Not applicableCanada
Fluvoxamine-50tablet50 mgoralPro Doc Limitee1998-04-10Not applicableCanada
Gen-fluvoxamine 100mgtablet100 mgoralGenpharm Ulc1999-09-152002-01-11Canada
Gen-fluvoxamine 50mgtablet50 mgoralGenpharm Ulc1999-09-152002-01-11Canada
Luvoxtablet50 mgoralBgp Pharma Ulc1991-12-31Not applicableCanada
Luvoxtablet100 mgoralBgp Pharma Ulc1991-12-31Not applicableCanada
Luvox CRcapsule, extended release150 mg/1oralJazz Pharmaceuticals, Inc.2008-02-28Not applicableUs
Luvox CRcapsule, extended release100 mg/1oralJazz Pharmaceuticals, Inc.2008-02-28Not applicableUs
Novo-fluvoxaminetablet50 mgoralTeva Canada Limited1999-04-30Not applicableCanada
Novo-fluvoxaminetablet100 mgoralTeva Canada Limited1999-04-30Not applicableCanada
Nu-fluvoxamine 100 Mg Tabtablet100 mgoralNu Pharm Inc1998-10-302012-09-04Canada
Nu-fluvoxamine 50 Mg Tabtablet50 mgoralNu Pharm Inc1998-10-302012-09-04Canada
PHL-fluvoxaminetablet100 mgoralPharmel Inc2005-03-23Not applicableCanada
PHL-fluvoxaminetablet50 mgoralPharmel Inc2005-03-23Not applicableCanada
PMS-fluvoxaminetablet50 mgoralPharmascience Inc1999-09-02Not applicableCanada
PMS-fluvoxaminetablet100 mgoralPharmascience Inc1999-10-12Not applicableCanada
Ratio-fluvoxaminetablet100 mgoralTeva Canada Limited1997-06-12Not applicableCanada
Ratio-fluvoxaminetablet50 mgoralTeva Canada Limited1997-06-12Not applicableCanada
Riva-fluvoxtablet100 mgoralLaboratoire Riva Inc2008-06-11Not applicableCanada
Riva-fluvoxtablet50 mgoralLaboratoire Riva Inc2008-06-11Not applicableCanada
Riva-fluvox 100mg Tabletstablet100 mgoralLaboratoire Riva Inc1999-08-272003-07-28Canada
Riva-fluvox 50mg Tabletstablet50 mgoralLaboratoire Riva Inc1999-08-272003-07-28Canada
Sandoz Fluvoxaminetablet100 mgoralSandoz Canada Incorporated2003-02-27Not applicableCanada
Sandoz Fluvoxaminetablet50 mgoralSandoz Canada Incorporated2003-02-27Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-fluvoxamine Tabletstablet50 mgoralApotex Inc1997-05-20Not applicableCanada
Apo-fluvoxamine Tabletstablet100 mgoralApotex Inc1998-05-20Not applicableCanada
Fluvoxamine Maleatetablet50 mg/1oralREMEDYREPACK INC.2011-11-30Not applicableUs
Fluvoxamine Maleatetablet, film coated25 mg/1oralEon Labs, Inc.2000-11-29Not applicableUs
Fluvoxamine Maleatetablet, film coated100 mg/1oralMylan Institutional Inc.2002-09-15Not applicableUs
Fluvoxamine Maleatetablet, film coated50 mg/1oralMylan Pharmaceuticals Inc.2000-12-20Not applicableUs
Fluvoxamine Maleatetablet100 mg/1oralGolden State Medical Supply, Inc.2001-05-07Not applicableUs
Fluvoxamine Maleatecapsule, extended release150 mg/1oralTorrent Pharmaceuticals Limited2014-10-31Not applicableUs
Fluvoxamine Maleatetablet50 mg/1oralAmerican Health Packaging2014-09-29Not applicableUs
Fluvoxamine Maleatetablet, film coated25 mg/1oralMylan Pharmaceuticals Inc.2000-12-20Not applicableUs
Fluvoxamine Maleatetablet50 mg/1oralGolden State Medical Supply, Inc.2001-05-07Not applicableUs
Fluvoxamine Maleatecapsule, extended release100 mg/1oralTorrent Pharmaceuticals Limited2014-10-31Not applicableUs
Fluvoxamine Maleatetablet, film coated50 mg/1oralbryant ranch prepack2000-11-29Not applicableUs
Fluvoxamine Maleatecapsule, extended release150 mg/1oralActavis Pharma, Inc.2014-08-05Not applicableUs
Fluvoxamine Maleatetablet25 mg/1oralGolden State Medical Supply, Inc.2001-05-07Not applicableUs
Fluvoxamine Maleatetablet, film coated100 mg/1oralbryant ranch prepack2010-03-12Not applicableUs
Fluvoxamine Maleatecapsule, extended release100 mg/1oralActavis Pharma, Inc.2014-08-05Not applicableUs
Fluvoxamine Maleatetablet100 mg/1oralCaraco Pharmaceutical Laboratories, Ltd.2006-02-23Not applicableUs
Fluvoxamine Maleatetablet100 mg/1oralApotex Corp2001-07-10Not applicableUs
Fluvoxamine Maleatetablet, film coated100 mg/1oralEon Labs, Inc.2000-11-29Not applicableUs
Fluvoxamine Maleatetablet50 mg/1oralCaraco Pharmaceutical Laboratories, Ltd.2006-02-23Not applicableUs
Fluvoxamine Maleatetablet, film coated100 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-03-12Not applicableUs
Fluvoxamine Maleatetablet50 mg/1oralApotex Corp2001-07-10Not applicableUs
Fluvoxamine Maleatetablet, film coated50 mg/1oralMylan Institutional Inc.2002-09-15Not applicableUs
Fluvoxamine Maleatetablet, film coated50 mg/1oralEon Labs, Inc.2000-11-29Not applicableUs
Fluvoxamine Maleatetablet25 mg/1oralCaraco Pharmaceutical Laboratories, Ltd.2006-02-23Not applicableUs
Fluvoxamine Maleatetablet, film coated100 mg/1oralMylan Pharmaceuticals Inc.2000-12-20Not applicableUs
Fluvoxamine Maleatetablet25 mg/1oralApotex Corp2001-07-10Not applicableUs
Fluvoxamine Maleate Extended-releasecapsule, extended release150 mg/1oralPar Pharmaceutical, Inc.2013-03-13Not applicableUs
Fluvoxamine Maleate Extended-releasecapsule, extended release100 mg/1oralPar Pharmaceutical, Inc.2013-03-13Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DumiroxAbbott
FaverinAbbott
FevarinAbbott
FloxyfralAbbott
MaveralAbbott
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Fluvoxamine maleate
ThumbNot applicableDBSALT000879
Categories
UNIIO4L1XPO44W
CAS number54739-18-3
WeightAverage: 318.3346
Monoisotopic: 318.155512541
Chemical FormulaC15H21F3N2O2
InChI KeyInChIKey=CJOFXWAVKWHTFT-XSFVSMFZSA-N
InChI
InChI=1S/C15H21F3N2O2/c1-21-10-3-2-4-14(20-22-11-9-19)12-5-7-13(8-6-12)15(16,17)18/h5-8H,2-4,9-11,19H2,1H3/b20-14+
IUPAC Name
(2-aminoethoxy)({5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene})amine
SMILES
COCCCCC(=NOCCN)C1=CC=C(C=C1)C(F)(F)F
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzene and substituted derivatives. These are aromatic compounds containing one monocyclic ring system consisting of benzene.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassNot Available
Direct ParentBenzene and substituted derivatives
Alternative Parents
Substituents
  • Monocyclic benzene moiety
  • Oxime ether
  • Ether
  • Dialkyl ether
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Primary aliphatic amine
  • Amine
  • Alkyl halide
  • Alkyl fluoride
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor management of depression and for Obsessive Compulsive Disorder (OCD). Has also been used in the management of bulimia nervosa.
PharmacodynamicsFluvoxamine, an aralkylketone-derivative agent, is one of a class of antidepressants known as selective serotonin reuptake inhibitors (SSRIs) that differs structurally from other SSRIs. It is used to treat the depression associated with mood disorders. It is also used on occassion in the treatment of body dysmorphic disorder and anxiety. The antidepressant, antiobsessive-compulsive, and antibulimic actions of Fluvoxamine are presumed to be linked to its inhibition of CNS neuronal uptake of serotonin. In vitro studies show that Fluvoxamine is a potent and selective inhibitor of neuronal serotonin reuptake and has only very weak effects on norepinephrine and dopamine neuronal reuptake. Fluvoxamine has no significant affinity for adrenergic (alpha1, alpha2, beta), cholinergic, GABA, dopaminergic, histaminergic, serotonergic (5HT1A, 5HT1B, 5HT2), or benzodiazepine receptors; antagonism of such receptors has been hypothesized to be associated with various anticholinergic, sedative, and cardiovascular effects for other psychotropic drugs. The chronic administration of Fluvoxamine was found to downregulate brain norepinephrine receptors, as has been observed with other drugs effective in the treatment of major depressive disorder. Fluvoxamine does not inhibit monoamine oxidase.
Mechanism of actionThe exact mechanism of action of fluvoxamine has not been fully determined, but appears to be linked to its inhibition of CNS neuronal uptake of serotonin. Fluvoxamine blocks the reuptake of serotonin at the serotonin reuptake pump of the neuronal membrane, enhancing the actions of serotonin on 5HT1A autoreceptors. In-vitro studies suggest that fluvoxamine is more potent than clomipramine, fluoxetine, and desipramine as a serotonin-reuptake inhibitor. Studies have also demonstrated that fluvoxamine has virtually no affinity for α1- or α2-adrenergic, β-adrenergic, muscarinic, dopamine D2, histamine H1, GABA-benzodiazepine, opiate, 5-HT1, or 5-HT2 receptors.
Related Articles
AbsorptionWell absorbed, bioavailability of fluvoxamine maleate is 53%.
Volume of distribution
  • 25 L/kg
Protein binding~77-80% (plasma protein)
Metabolism

Hepatic

SubstrateEnzymesProduct
Fluvoxamine
fluvoxamino acidDetails
Route of eliminationThe main human metabolite was fluvoxamine acid which, together with its N-acetylated analog, accounted for about 60% of the urinary excretion products. Approximately 2% of fluvoxamine was excreted in urine unchanged. Following a 14C-labelled oral dose of fluvoxamine maleate (5 mg), an average of 94% of drug-related products was recovered in the urine within 71 hours.
Half life15.6 hours
ClearanceNot Available
ToxicitySide effects include anorexia, constipation, dry mouth, headache, nausea, nervousness, skin rash, sleep problems, somnolence, liver toxicity, mania, increase urination, seizures, sweating increase, tremors, or Tourette's syndrome.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9775
Caco-2 permeable-0.5149
P-glycoprotein substrateSubstrate0.6079
P-glycoprotein inhibitor IInhibitor0.7883
P-glycoprotein inhibitor IINon-inhibitor0.8382
Renal organic cation transporterNon-inhibitor0.5325
CYP450 2C9 substrateNon-substrate0.8595
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateNon-substrate0.6723
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorInhibitor0.8949
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorInhibitor0.8994
CYP450 3A4 inhibitorInhibitor0.7959
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8481
Ames testNon AMES toxic0.5
CarcinogenicityNon-carcinogens0.637
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6997 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8427
hERG inhibition (predictor II)Inhibitor0.7995
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Jazz pharmaceuticals
  • Actavis elizabeth llc
  • Apotex inc
  • Barr laboratories inc
  • Caraco pharmaceutical laboratories ltd
  • Genpharm inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Synthon pharmaceuticals ltd
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Ani pharmaceuticals inc
  • Solvay pharmaceuticals
Packagers
Dosage forms
FormRouteStrength
Tabletoral100.0 mg
Tabletoral50.0 mg
Capsule, extended releaseoral100 mg/1
Capsule, extended releaseoral150 mg/1
Tabletoral100 mg/1
Tabletoral25 mg/1
Tabletoral50 mg/1
Tablet, coatedoral100 mg/1
Tablet, coatedoral25 mg/1
Tablet, coatedoral50 mg/1
Tablet, film coatedoral100 mg/1
Tablet, film coatedoral25 mg/1
Tablet, film coatedoral50 mg/1
Tabletoral100 mg
Tabletoral50 mg
Prices
Unit descriptionCostUnit
Luvox CR 150 mg 24 Hour Capsule6.34USD capsule
Luvox cr 150 mg capsule6.24USD capsule
Luvox CR 100 mg 24 Hour Capsule6.05USD capsule
Luvox cr 100 mg capsule5.82USD capsule
Fluvoxamine maleate 100 mg tablet2.69USD tablet
Fluvoxamine mal 100 mg tablet2.63USD tablet
Fluvoxamine maleate 50 mg tablet2.61USD tablet
Fluvoxamine maleate 25 mg tablet2.34USD tablet
Luvox 100 mg Tablet1.7USD tablet
Luvox 50 mg Tablet0.95USD tablet
Apo-Fluvoxamine 100 mg Tablet0.93USD tablet
Co Fluvoxamine 100 mg Tablet0.93USD tablet
Novo-Fluvoxamine 100 mg Tablet0.93USD tablet
Nu-Fluvoxamine 100 mg Tablet0.93USD tablet
Pms-Fluvoxamine 100 mg Tablet0.93USD tablet
Ratio-Fluvoxamine 100 mg Tablet0.93USD tablet
Sandoz Fluvoxamine 100 mg Tablet0.93USD tablet
Apo-Fluvoxamine 50 mg Tablet0.52USD tablet
Co Fluvoxamine 50 mg Tablet0.52USD tablet
Novo-Fluvoxamine 50 mg Tablet0.52USD tablet
Nu-Fluvoxamine 50 mg Tablet0.52USD tablet
Pms-Fluvoxamine 50 mg Tablet0.52USD tablet
Ratio-Fluvoxamine 50 mg Tablet0.52USD tablet
Sandoz Fluvoxamine 50 mg Tablet0.52USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7465462 No2000-05-102020-05-10Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point120-121.5 °CWelle, H.B.A. and Claassen, V.; U.S. Patent 4,085,225; April 18, 1978; assigned to U.S. Phillips Corp.
logP3.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00734 mg/mLALOGPS
logP2.89ALOGPS
logP2.8ChemAxon
logS-4.6ALOGPS
pKa (Strongest Basic)9.16ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area56.84 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity79.2 m3·mol-1ChemAxon
Polarizability32.44 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Welle, H.B.A. and Claassen, V.; U.S. Patent 4,085,225; April 18, 1978; assigned to U.S. Phillips Corp.

General References
  1. Dell'Osso B, Allen A, Hollander E: Fluvoxamine: a selective serotonin re-uptake inhibitor for the treatment of obsessive-compulsive disorder. Expert Opin Pharmacother. 2005 Dec;6(15):2727-40. [PubMed:16316311 ]
  2. Irons J: Fluvoxamine in the treatment of anxiety disorders. Neuropsychiatr Dis Treat. 2005 Dec;1(4):289-99. [PubMed:18568110 ]
External Links
ATC CodesN06AB08
AHFS Codes
  • 28:16.04.20
PDB EntriesNot Available
FDA labelDownload (633 KB)
MSDSDownload (48.5 KB)
Interactions
Drug Interactions
Drug
AbciximabFluvoxamine may increase the anticoagulant activities of Abciximab.
AbirateroneThe serum concentration of Fluvoxamine can be increased when it is combined with Abiraterone.
AcenocoumarolFluvoxamine may increase the anticoagulant activities of Acenocoumarol.
AcepromazineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Acepromazine.
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Fluvoxamine.
AcetophenazineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Acetophenazine.
Acetylsalicylic acidFluvoxamine may increase the antiplatelet activities of Acetylsalicylic acid.
AgomelatineThe serum concentration of Agomelatine can be increased when it is combined with Fluvoxamine.
AlmotriptanThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Almotriptan.
AlosetronThe metabolism of Alosetron can be decreased when combined with Fluvoxamine.
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Fluvoxamine.
AlteplaseFluvoxamine may increase the anticoagulant activities of Alteplase.
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Fluvoxamine.
AmiodaroneThe metabolism of Fluvoxamine can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Amitriptyline.
AmoxapineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Amoxapine.
AnistreplaseFluvoxamine may increase the anticoagulant activities of Anistreplase.
ApixabanThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Apixaban.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Fluvoxamine.
ArtemetherThe metabolism of Fluvoxamine can be decreased when combined with Artemether.
AsenapineThe serum concentration of Asenapine can be increased when it is combined with Fluvoxamine.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Fluvoxamine.
BendamustineThe serum concentration of Bendamustine can be increased when it is combined with Fluvoxamine.
BenzquinamideThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Benzquinamide.
BetaxololThe metabolism of Betaxolol can be decreased when combined with Fluvoxamine.
BortezomibThe metabolism of Fluvoxamine can be decreased when combined with Bortezomib.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Brexpiprazole.
BromazepamThe serum concentration of Bromazepam can be increased when it is combined with Fluvoxamine.
BromocriptineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Bromocriptine.
BupropionThe risk or severity of adverse effects can be increased when Bupropion is combined with Fluvoxamine.
BuspironeBuspirone may increase the serotonergic activities of Fluvoxamine.
ButalbitalThe metabolism of Butalbital can be decreased when combined with Fluvoxamine.
CabergolineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Cabergoline.
CaffeineThe metabolism of Caffeine can be decreased when combined with Fluvoxamine.
CarbamazepineThe metabolism of Carbamazepine can be decreased when combined with Fluvoxamine.
CarisoprodolThe metabolism of Carisoprodol can be decreased when combined with Fluvoxamine.
CarphenazineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Carphenazine.
CelecoxibThe metabolism of Fluvoxamine can be decreased when combined with Celecoxib.
ChlormezanoneThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Chlormezanone.
ChloroquineThe metabolism of Fluvoxamine can be decreased when combined with Chloroquine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Chlorprothixene.
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Fluvoxamine.
CimetidineThe metabolism of Fluvoxamine can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Fluvoxamine can be decreased when combined with Cinacalcet.
CiprofloxacinThe metabolism of Fluvoxamine can be decreased when combined with Ciprofloxacin.
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Fluvoxamine.
Citric AcidFluvoxamine may increase the anticoagulant activities of Citric Acid.
ClobazamThe metabolism of Clobazam can be decreased when combined with Fluvoxamine.
ClomipramineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Clomipramine.
ClopidogrelThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Clopidogrel.
ClozapineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Clozapine.
CobicistatThe serum concentration of Fluvoxamine can be increased when it is combined with Cobicistat.
CocaineThe metabolism of Fluvoxamine can be decreased when combined with Cocaine.
CollagenaseThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Collagenase.
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Fluvoxamine.
CyproheptadineThe therapeutic efficacy of Fluvoxamine can be decreased when used in combination with Cyproheptadine.
Cyproterone acetateThe serum concentration of Fluvoxamine can be decreased when it is combined with Cyproterone acetate.
Dabigatran etexilateFluvoxamine may increase the anticoagulant activities of Dabigatran etexilate.
DacarbazineThe metabolism of Dacarbazine can be decreased when combined with Fluvoxamine.
DalteparinFluvoxamine may increase the anticoagulant activities of Dalteparin.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Fluvoxamine.
DarifenacinThe metabolism of Fluvoxamine can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Fluvoxamine can be increased when it is combined with Darunavir.
DasatinibDasatinib may increase the anticoagulant activities of Fluvoxamine.
DeferasiroxThe serum concentration of Fluvoxamine can be increased when it is combined with Deferasirox.
DelavirdineThe metabolism of Fluvoxamine can be decreased when combined with Delavirdine.
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Deoxycholic Acid.
DesipramineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Desipramine.
DesmopressinThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Desmopressin.
DesogestrelThe metabolism of Fluvoxamine can be decreased when combined with Desogestrel.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Desvenlafaxine.
DextromethorphanThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Dextromethorphan.
DiazepamThe metabolism of Diazepam can be decreased when combined with Fluvoxamine.
DicoumarolFluvoxamine may increase the anticoagulant activities of Dicoumarol.
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Fluvoxamine.
DihydroergotamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Dihydroergotamine.
DiphenhydramineThe metabolism of Fluvoxamine can be decreased when combined with Diphenhydramine.
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Fluvoxamine.
DolasetronDolasetron may increase the serotonergic activities of Fluvoxamine.
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Fluvoxamine.
DoxepinThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Doxepin.
DronedaroneThe metabolism of Fluvoxamine can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Droperidol.
DuloxetineThe serum concentration of Duloxetine can be increased when it is combined with Fluvoxamine.
Edetic AcidFluvoxamine may increase the anticoagulant activities of Edetic Acid.
EletriptanThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Eletriptan.
EliglustatThe metabolism of Fluvoxamine can be decreased when combined with Eliglustat.
EnoxaparinFluvoxamine may increase the anticoagulant activities of Enoxaparin.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Ergoloid mesylate.
ErgonovineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Ergonovine.
ErgotamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Ergotamine.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Fluvoxamine.
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Fluvoxamine.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Fluvoxamine.
Ethinyl EstradiolThe metabolism of Fluvoxamine can be decreased when combined with Ethinyl Estradiol.
Ethyl biscoumacetateFluvoxamine may increase the anticoagulant activities of Ethyl biscoumacetate.
Ethynodiol diacetateThe metabolism of Fluvoxamine can be decreased when combined with Ethynodiol.
EtizolamThe serum concentration of Etizolam can be increased when it is combined with Fluvoxamine.
FencamfamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Fencamfamine.
FentanylThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Fentanyl.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Fluvoxamine.
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Fluvoxamine.
FluoxetineThe metabolism of Fluvoxamine can be decreased when combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Fluphenazine.
FluspirileneThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Fluspirilene.
FlutamideThe metabolism of Flutamide can be decreased when combined with Fluvoxamine.
Fondaparinux sodiumFluvoxamine may increase the anticoagulant activities of Fondaparinux sodium.
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Fluvoxamine.
FrovatriptanThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Frovatriptan.
GemfibrozilThe metabolism of Fluvoxamine can be decreased when combined with Gemfibrozil.
GlucosamineGlucosamine may increase the antiplatelet activities of Fluvoxamine.
GranisetronGranisetron may increase the serotonergic activities of Fluvoxamine.
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Fluvoxamine.
HeparinFluvoxamine may increase the anticoagulant activities of Heparin.
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Fluvoxamine.
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Ibritumomab.
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Fluvoxamine.
IcosapentFluvoxamine may increase the antiplatelet activities of Icosapent.
IloperidoneThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Iloperidone.
ImipramineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Imipramine.
Insulin HumanFluvoxamine may increase the hypoglycemic activities of Insulin Regular.
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Fluvoxamine.
Ioflupane I 123Fluvoxamine may decrease effectiveness of Ioflupane I 123 as a diagnostic agent.
IsocarboxazidThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Isocarboxazid.
IsomethepteneThe metabolism of Isometheptene can be decreased when combined with Fluvoxamine.
IsoniazidThe metabolism of Fluvoxamine can be decreased when combined with Isoniazid.
KetoconazoleThe metabolism of Fluvoxamine can be decreased when combined with Ketoconazole.
L-TryptophanL-Tryptophan may increase the serotonergic activities of Fluvoxamine.
LevomilnacipranThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Levomilnacipran.
LidocaineThe metabolism of Lidocaine can be decreased when combined with Fluvoxamine.
LimaprostLimaprost may increase the antiplatelet activities of Fluvoxamine.
LinezolidLinezolid may increase the serotonergic activities of Fluvoxamine.
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Fluvoxamine.
LithiumLithium may increase the serotonergic activities of Fluvoxamine.
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Fluvoxamine.
LopinavirThe metabolism of Fluvoxamine can be decreased when combined with Lopinavir.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Fluvoxamine.
LorcaserinThe metabolism of Fluvoxamine can be decreased when combined with Lorcaserin.
LoxapineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Loxapine.
LumefantrineThe metabolism of Fluvoxamine can be decreased when combined with Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Lurasidone.
MaprotilineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Maprotiline.
MesoridazineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Mesoridazine.
MethadoneThe metabolism of Methadone can be decreased when combined with Fluvoxamine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Methotrimeprazine.
MethoxsalenThe metabolism of Fluvoxamine can be decreased when combined with Methoxsalen.
MethsuximideThe metabolism of Methsuximide can be decreased when combined with Fluvoxamine.
Methylene blueFluvoxamine may increase the serotonergic activities of Methylene blue.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Fluvoxamine.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Fluvoxamine.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Fluvoxamine.
MexiletineThe metabolism of Mexiletine can be decreased when combined with Fluvoxamine.
MilnacipranThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Milnacipran.
MirabegronThe metabolism of Fluvoxamine can be decreased when combined with Mirabegron.
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Fluvoxamine.
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Fluvoxamine.
MolindoneThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Molindone.
MorphineMorphine may increase the serotonergic activities of Fluvoxamine.
NaratriptanThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Naratriptan.
NefazodoneThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Nefazodone.
NetupitantNetupitant may increase the serotonergic activities of Fluvoxamine.
NicardipineThe metabolism of Fluvoxamine can be decreased when combined with Nicardipine.
NilotinibThe metabolism of Fluvoxamine can be decreased when combined with Nilotinib.
NilutamideThe metabolism of Nilutamide can be decreased when combined with Fluvoxamine.
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Fluvoxamine.
NortriptylineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Nortriptyline.
ObinutuzumabThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Obinutuzumab.
OfloxacinThe metabolism of Fluvoxamine can be decreased when combined with Ofloxacin.
OlanzapineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Olanzapine.
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Fluvoxamine.
OndansetronThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Ondansetron.
OsimertinibThe serum concentration of Fluvoxamine can be decreased when it is combined with Osimertinib.
PaliperidoneThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Paliperidone.
PalonosetronPalonosetron may increase the serotonergic activities of Fluvoxamine.
PanobinostatThe serum concentration of Fluvoxamine can be increased when it is combined with Panobinostat.
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Fluvoxamine.
ParoxetineThe metabolism of Fluvoxamine can be decreased when combined with Paroxetine.
Peginterferon alfa-2bThe serum concentration of Fluvoxamine can be decreased when it is combined with Peginterferon alfa-2b.
PentamidineThe metabolism of Pentamidine can be decreased when combined with Fluvoxamine.
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Fluvoxamine.
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Fluvoxamine.
PerphenazineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Pethidine.
PhenelzinePhenelzine may increase the serotonergic activities of Fluvoxamine.
PhenindioneFluvoxamine may increase the anticoagulant activities of Phenindione.
PhenobarbitalThe metabolism of Fluvoxamine can be increased when combined with Phenobarbital.
PhenprocoumonFluvoxamine may increase the anticoagulant activities of Phenprocoumon.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Fluvoxamine.
PimozideThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Pimozide.
PiperacetazineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Piperacetazine.
PirfenidoneThe serum concentration of Pirfenidone can be increased when it is combined with Fluvoxamine.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Fluvoxamine.
PrimaquineThe metabolism of Fluvoxamine can be decreased when combined with Primaquine.
PrimidoneThe metabolism of Fluvoxamine can be increased when combined with Primidone.
ProcarbazineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Procarbazine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Prochlorperazine.
PromazineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Promethazine.
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Fluvoxamine.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Fluvoxamine.
ProtriptylineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Protriptyline.
QuetiapineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Quetiapine.
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Fluvoxamine.
QuinineThe metabolism of Fluvoxamine can be decreased when combined with Quinine.
RamelteonThe serum concentration of Ramelteon can be increased when it is combined with Fluvoxamine.
RasagilineThe serum concentration of Rasagiline can be increased when it is combined with Fluvoxamine.
RemoxiprideThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Remoxipride.
ReserpineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Reserpine.
ReteplaseFluvoxamine may increase the anticoagulant activities of Reteplase.
RidogrelFluvoxamine may increase the anticoagulant activities of Ridogrel.
RifampicinThe metabolism of Fluvoxamine can be increased when combined with Rifampicin.
RisperidoneThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Risperidone.
RitonavirThe metabolism of Fluvoxamine can be decreased when combined with Ritonavir.
RivaroxabanFluvoxamine may increase the anticoagulant activities of Rivaroxaban.
RizatriptanThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Rizatriptan.
RoflumilastThe serum concentration of the active metabolites of Roflumilast can be increased when Roflumilast is used in combination with Fluvoxamine.
RolapitantThe metabolism of Fluvoxamine can be decreased when combined with Rolapitant.
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Fluvoxamine.
RopivacaineThe serum concentration of Ropivacaine can be increased when it is combined with Fluvoxamine.
SelegilineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Selegiline.
SertindoleThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Sertindole.
SertralineThe metabolism of Fluvoxamine can be decreased when combined with Sertraline.
StiripentolThe metabolism of Stiripentol can be decreased when combined with Fluvoxamine.
StreptokinaseFluvoxamine may increase the anticoagulant activities of Streptokinase.
SulodexideFluvoxamine may increase the anticoagulant activities of Sulodexide.
SulpirideThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Sumatriptan.
TapentadolThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Tapentadol.
TasimelteonThe serum concentration of Tasimelteon can be increased when it is combined with Fluvoxamine.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Fluvoxamine.
TenecteplaseFluvoxamine may increase the anticoagulant activities of Tenecteplase.
TerbinafineThe metabolism of Fluvoxamine can be decreased when combined with Terbinafine.
TeriflunomideThe serum concentration of Fluvoxamine can be decreased when it is combined with Teriflunomide.
TheophyllineThe metabolism of Theophylline can be decreased when combined with Fluvoxamine.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Fluvoxamine.
ThiothixeneThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Thiothixene.
TiclopidineThe metabolism of Fluvoxamine can be decreased when combined with Ticlopidine.
TipranavirThe metabolism of Fluvoxamine can be decreased when combined with Tipranavir.
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Fluvoxamine.
TositumomabThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Tositumomab.
TramadolFluvoxamine may increase the neuroexcitatory activities of Tramadol.
TranylcypromineTranylcypromine may increase the serotonergic activities of Fluvoxamine.
TrazodoneFluvoxamine may increase the serotonergic activities of Trazodone.
TreprostinilFluvoxamine may increase the anticoagulant activities of Treprostinil.
TrichlormethiazideFluvoxamine may increase the activities of Trichlormethiazide.
TrifluoperazineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Triflupromazine.
TrimipramineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Trimipramine.
UrokinaseFluvoxamine may increase the anticoagulant activities of Urokinase.
VemurafenibThe serum concentration of Fluvoxamine can be increased when it is combined with Vemurafenib.
VenlafaxineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Venlafaxine.
VilazodoneThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Vilazodone.
Vitamin EVitamin E may increase the antiplatelet activities of Fluvoxamine.
VoriconazoleThe metabolism of Voriconazole can be decreased when combined with Fluvoxamine.
VortioxetineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Vortioxetine.
WarfarinFluvoxamine may increase the anticoagulant activities of Warfarin.
ZiprasidoneThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Ziprasidone.
ZolmitriptanThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Zolmitriptan.
ZolpidemFluvoxamine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Zuclopenthixol.
Food Interactions
  • Avoid alcohol.
  • Avoid high doses of caffeine.
  • Grapefruit and grapefruit juice should be avoided throughout treatment as grapefruit can significantly increase serum levels of this product.
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Kakiuchi T, Tsukada H, Fukumoto D, Nishiyama S: Effects of aging on serotonin transporter availability and its response to fluvoxamine in the living brain: PET study with [(11)C](+)McN5652 and [(11)C](-)McN5652 in conscious monkeys. Synapse. 2001 Jun 1;40(3):170-9. [PubMed:11304754 ]
  2. Yoshida K, Ito K, Sato K, Takahashi H, Kamata M, Higuchi H, Shimizu T, Itoh K, Inoue K, Tezuka T, Suzuki T, Ohkubo T, Sugawara K, Otani K: Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Prog Neuropsychopharmacol Biol Psychiatry. 2002 Feb;26(2):383-6. [PubMed:11817517 ]
  3. Miolo G, Caffieri S, Levorato L, Imbesi M, Giusti P, Uz T, Manev R, Manev H: Photoisomerization of fluvoxamine generates an isomer that has reduced activity on the 5-hydroxytryptamine transporter and does not affect cell proliferation. Eur J Pharmacol. 2002 Aug 30;450(3):223-9. [PubMed:12208313 ]
  4. Suhara T, Takano A, Sudo Y, Ichimiya T, Inoue M, Yasuno F, Ikoma Y, Okubo Y: High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. Arch Gen Psychiatry. 2003 Apr;60(4):386-91. [PubMed:12695316 ]
  5. Inoue K: [Analysis and its application for prevention of side-effects of drugs and for evaluation of drug responsiveness]. Yakugaku Zasshi. 2004 Jun;124(6):293-9. [PubMed:15170064 ]
  6. McMahon LR, Cunningham KA: Role of 5-HT(2a) and 5-HT(2B/2C) receptors in the behavioral interactions between serotonin and catecholamine reuptake inhibitors. Neuropsychopharmacology. 2001 Mar;24(3):319-29. [PubMed:11166521 ]
  7. Millan MJ, Veiga S, Girardon S, Brocco M: Blockade of serotonin 5-HT1B and 5-HT2A receptors suppresses the induction of locomotor activity by 5-HT reuptake inhibitors, citalopram and fluvoxamine, in NMRI mice exposed to a novel environment: a comparison to other 5-HT receptor subtypes. Psychopharmacology (Berl). 2003 Aug;168(4):397-409. Epub 2003 Apr 30. [PubMed:12721776 ]
  8. Dell'Osso B, Allen A, Hollander E: Fluvoxamine: a selective serotonin re-uptake inhibitor for the treatment of obsessive-compulsive disorder. Expert Opin Pharmacother. 2005 Dec;6(15):2727-40. [PubMed:16316311 ]
  9. Irons J: Fluvoxamine in the treatment of anxiety disorders. Neuropsychiatr Dis Treat. 2005 Dec;1(4):289-99. [PubMed:18568110 ]
  10. Williams K, Wheeler DM, Silove N, Hazell P: Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database Syst Rev. 2010 Aug 4;(8):CD004677. doi: 10.1002/14651858.CD004677.pub2. [PubMed:20687077 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Baumann P: Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996 Dec;31(6):444-69. [PubMed:8968657 ]
  2. Rasmussen BB, Brosen K: Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther Drug Monit. 2000 Apr;22(2):143-54. [PubMed:10774624 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Rasmussen BB, Nielsen TL, Brosen K: Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro. Pharmacol Toxicol. 1998 Dec;83(6):240-5. [PubMed:9868741 ]
  2. Baumann P: Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996 Dec;31(6):444-69. [PubMed:8968657 ]
  3. Brosen K: Drug interactions and the cytochrome P450 system. The role of cytochrome P450 1A2. Clin Pharmacokinet. 1995;29 Suppl 1:20-5. [PubMed:8846619 ]
  4. Micallef J, Fakra E, Blin O: [Use of antidepressant drugs in schizophrenic patients with depression]. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9. [PubMed:16910628 ]
  5. Rasmussen BB, Brosen K: Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther Drug Monit. 2000 Apr;22(2):143-54. [PubMed:10774624 ]
  6. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  7. Yasui-Furukori N, Inoue Y, Kaneko S, Otani K: Determination of fluvoxamine and its metabolite fluvoxamino acid by liquid-liquid extraction and column-switching high-performance liquid chromatography. J Pharm Biomed Anal. 2005 Feb 7;37(1):121-5. [PubMed:15664751 ]
  8. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Baumann P: Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996 Dec;31(6):444-69. [PubMed:8968657 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Baumann P: Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996 Dec;31(6):444-69. [PubMed:8968657 ]
  2. Micallef J, Fakra E, Blin O: [Use of antidepressant drugs in schizophrenic patients with depression]. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9. [PubMed:16910628 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Micallef J, Fakra E, Blin O: [Use of antidepressant drugs in schizophrenic patients with depression]. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9. [PubMed:16910628 ]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Baumann P: Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996 Dec;31(6):444-69. [PubMed:8968657 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. [PubMed:12438524 ]
  2. Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE: Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther. 2003 Apr;305(1):197-204. [PubMed:12649369 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on July 26, 2016 01:52